New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
SPECIFIC ENHANCEMENT OF THE THERAPEUTIC EFFECT OF ANTI-IDIOTYPE ANTIBODIES ON A MURINE B-CELL LYMPHOMA BY IL-2
SPECIFIC ENHANCEMENT OF THE THERAPEUTIC EFFECT OF ANTI-IDIOTYPE ANTIBODIES ON A MURINE B-CELL LYMPHOMA BY IL-2 JOURNAL OF IMMUNOLOGY Berinstein, N., Starnes, C. O., Levy, R. 1988; 140 (8): 2839-2845Abstract
We have previously reported on the augmentation of monoclonal anti-Id antibodies by IL-2 in the therapy of a murine B cell lymphoma. The mechanism of this augmentation was through the expansion by IL-2 of effector cells mediating antibody-dependent cellular cytotoxicity. In this paper we explore the power of IL-2 to enhance anti-Id therapy on larger tumor burdens and at sites distant from the site of injection. The combination treatment was able to induce regression of established 1-cm s.c. tumors associated with microscopic metastatic tumor in lungs, liver, and spleen. Further studies into the mechanism of activity showed that IL-2 was unable to augment in vivo or in vitro tumor lysis by F(ab')2 fragments, thus emphasizing the importance of Fc interactions with antibody-dependent cellular cytotoxicity effector cells. FcR-bearing NK cells were increased in the peritoneum of IL-2-treated mice. The augmented therapeutic effect by the combination treatment was specific for tumor cells expressing the target Id, and non-specific cytotoxicity on Id-negative variants was not seen.
View details for Web of Science ID A1988M900100057
View details for PubMedID 3258621